Cancer survivors who leave specialist oncology clinics for follow-up in primary care are not disappearing from the cancer system, according to a new retrospective cohort study from Ontario, Canada. The research, published in the Journal of Cancer Survivorship, found that most patients transitioned to primary care did not return to oncology, and only a small proportion were later found to have recurrent or newly developed disease. The findings offer fresh evidence for a model of survivorship care that has become increasingly important as the number of people living beyond cancer treatment continues to grow. At the Juravinski Cancer Centre, researchers reviewed the records of 2,604 cancer survivors who had been transitioned from oncology follow-up to primary care between 2013 and 2020. Of those patients, 440—16.9 percent—had at least one subsequent oncology visit. Recurrence or a new cancer was detected in 28.2 percent of these returning patients, equivalent to 4.8 percent of the entire transitioned population.
The study addresses a practical question at the center of modern survivorship medicine: what happens after cancer patients are formally released from routine specialist surveillance? Advances in diagnosis and treatment have created a rapidly expanding population of survivors who may live for decades after their initial therapy. Maintaining every survivor in a hospital-based oncology clinic, however, can strain specialist capacity and may not always provide the most appropriate long-term care. Primary care clinicians are often better positioned to manage hypertension, diabetes, cardiovascular disease, mental-health concerns, medication effects, vaccination, screening for other illnesses, and the broader consequences of cancer treatment. The transition is not intended to sever contact with oncology. Instead, it shifts routine monitoring to primary care while preserving a route back to specialists when new symptoms, abnormal tests, treatment complications, or other concerns arise. The Ontario data suggest that this safety-net approach functioned in practice, with patients able to reconnect with oncology when clinical circumstances required it.
Among the 440 patients who returned, nearly one-third of visits were not conventional “re-referrals” for suspected cancer recurrence. Specifically, 32.7 percent involved genetic counseling, participation in clinical trials, or palliative-care follow-up. This distinction matters because a return to an oncology department does not automatically indicate that a cancer has come back. Patients may need specialist expertise for inherited cancer-risk assessment, access to experimental treatments, symptom management, or end-of-life support even when there is no evidence of active disease. Counting every oncology encounter as a suspected recurrence could therefore exaggerate the apparent failure of primary-care-led survivorship. The researchers’ chart review allowed them to separate these different pathways and examine why patients came back. Their analysis presents oncology as a flexible resource rather than a clinic used exclusively for detecting relapse. It also shows that survivorship is not a single phase with identical needs for every patient; the appropriate care setting can change as medical, genetic, psychological, and social circumstances evolve.
For patients who returned because of a clinical concern, symptoms were the most common trigger. Investigation of symptoms accounted for 32.7 percent of subsequent oncology visits, while investigation of abnormal or concerning tests accounted for another 23.2 percent. These encounters illustrate how primary care can serve as the first point of assessment without becoming a barrier to specialist review. A new cough, unexplained pain, weight loss, fatigue, bleeding, or an unexpected laboratory or imaging result may be caused by many conditions unrelated to cancer. Primary-care clinicians can evaluate these possibilities, order initial investigations, and consult oncology when the pattern raises concern. In technical terms, this approach uses risk-based triage rather than automatic surveillance for every survivor. It reduces routine specialist appointments while maintaining escalation pathways for potentially significant findings. The results indicate that this system did not prevent patients with important concerns from reaching oncology services. Instead, it allowed specialist attention to be concentrated among those whose symptoms or test results justified further evaluation.
Cancer recurrence or newly diagnosed disease was identified in 124 of the 440 patients who had subsequent oncology visits, representing 28.2 percent of the returning group. When calculated against all 2,604 survivors transitioned to primary care, this becomes 4.8 percent. The difference between these two percentages is essential for interpreting the study. Among patients selected for oncology review because something had prompted concern, the likelihood of finding recurrence or a new disease was substantially higher than in the full population. That is expected in a clinically enriched group: people who return are not a random sample of all survivors but are more likely to have symptoms, abnormal tests, or other risk signals. Across the entire transitioned cohort, however, more than 95 percent did not have recurrence or new disease documented during the study’s observed experience. Most of the patients in whom recurrent or new disease was detected went on to receive treatment, demonstrating that transition did not necessarily delay therapeutic intervention once a clinically important problem was recognized.
The findings also challenge the assumption that specialist follow-up must be continuous to be safe. Traditional surveillance models often rely on scheduled oncology appointments and protocol-driven testing, but evidence from survivorship research has increasingly questioned whether routine specialist visits improve outcomes for all patients. Recurrence risk varies by tumor type, stage, molecular characteristics, treatment history, and time since diagnosis. Surveillance strategies that ignore these differences can produce unnecessary imaging, false-positive results, anxiety, and inefficient use of healthcare resources. Primary care-led follow-up can instead combine individualized survivorship plans with symptom awareness and clear referral criteria. Such plans may include a treatment summary, a survivorship care plan, screening recommendations, information about late effects, and direct contact details for oncology services. The Ontario study does not prove that every cancer survivor should be transferred to primary care, nor does it establish that all recurrence will be detected equally quickly. It does, however, provide real-world evidence that a structured transition can coexist with timely specialist re-entry.
The study’s retrospective design offers a broad view of what happened in routine clinical practice, but it also limits the conclusions that can be drawn. Researchers relied on existing medical records, which may not capture every symptom, consultation, or healthcare interaction. The work was conducted at a single cancer center, so its results may not apply directly to hospitals with different referral systems, patient populations, staffing levels, or access to primary care. The study period ended in 2020, and changes in treatment, electronic records, virtual care, and survivorship policies may influence current patterns. In addition, the abstract does not provide detailed breakdowns by cancer type, stage, age, socioeconomic status, or the exact time between transition and return. Those factors could affect both recurrence risk and the ease with which patients access specialists. Even with these limitations, the size of the cohort and the detailed review of subsequent oncology encounters make the findings relevant to health systems seeking practical evidence rather than theoretical models.
The researchers emphasize that patients were able to reconnect with oncology regardless of the underlying reason for their return. That point may be particularly important for survivors who worry that leaving a cancer center means losing access to cancer expertise. A successful transition depends not only on assigning responsibility to primary care but also on making the boundaries between services visible and dependable. Communication between oncologists and family physicians is critical. Primary-care teams need to know the original diagnosis, treatments received, potential late effects, recommended surveillance, and signs that should prompt referral. Patients need to understand which symptoms require urgent attention, whom to contact, and how to request specialist review. Without those connections, transition could become abandonment; with them, it can become coordinated shared care. The study’s low overall rate of recurrence after transition, combined with the documented ability to return when necessary, supports the concept that primary care can provide ongoing survivorship management while oncology remains available for complex or high-risk problems.
The implications extend beyond cancer clinics. As survivorship populations expand, health systems must decide how to allocate specialist time without compromising safety. The study suggests that a relatively small number of patients will require renewed oncology involvement after transition, and that many of those visits will concern issues other than recurrence. This could help cancer centers design more responsive referral pathways, rapid-access clinics, virtual consultations, and shared-care programs. It also highlights the value of distinguishing surveillance from survivorship care. Survivorship includes prevention, chronic-disease management, rehabilitation, psychosocial support, genetic counseling, management of treatment-related complications, and preparation for possible recurrence—not simply repeated scans and specialist examinations. For patients, the message is reassuring: moving follow-up to primary care does not mean that cancer expertise is permanently out of reach. In this Ontario cohort, primary-care-led survivorship was associated with a low rate of detected recurrence across the full transitioned population, while those who needed oncology care were generally able to find their way back.
The study therefore adds a data-driven note to a rapidly evolving debate about who should care for cancer survivors after active treatment ends. Its results do not eliminate the need for careful selection, individualized planning, or communication between clinicians. They do suggest that routine oncology follow-up for every survivor may not be necessary when primary-care teams are supported and re-referral mechanisms are clear. The model resembles a clinical safety network: most patients receive broad, continuous care close to home, while specialist services remain ready to respond to warning signals, complex decisions, and changing needs. For a healthcare system confronting rising cancer prevalence and finite oncology capacity, that balance could prove increasingly influential. The central finding is straightforward but consequential: among more than 2,600 survivors transitioned to primary care, only a minority returned to oncology, and recurrence or new disease affected fewer than one in twenty of the overall group. That pattern supports transition as a viable component of long-term cancer care.
Subject of Research: Cancer survivorship and transition from oncology follow-up to primary care
Article Title: Subsequent oncology visits among cancer survivors transitioned to primary care: a retrospective cohort study
Article References: Fishbein, F. S., Bainbridge, D., Mukherjee, S. D., Vadacchino, E., Leong, R., Sussman, J., et al. “Subsequent oncology visits among cancer survivors transitioned to primary care: a retrospective cohort study.” Journal of Cancer Survivorship (2026). Published 20 August 2026.
Image Credits: AI Generated
DOI: 10.1007/s11764-026-02105-2
Keywords: Cancer survivorship, primary care, oncology follow-up, transitions of care, recurrence, survivorship care models, cancer surveillance, shared care
